Int J Neurosci
- HUYNH TLT, Feasel CD, Jeng B, Motl RW, et al
Cross-sectional, comparative study of health-related quality of life across the
adult lifespan in multiple sclerosis.
Int J Neurosci. 2024 Mar 5:1-10. doi: 10.1080/00207454.2024.2327404.
J Immunol
- DAR AA, Ortega Y, Aktas S, Wu K, et al
CRL4b Inhibition Ameliorates Experimental Autoimmune Encephalomyelitis
Progression.
J Immunol. 2024 Jan 24:ji2300754. doi: 10.4049/jimmunol.2300754.
J Neuroimmunol
- HAHAM N, Zveik O, Rechtman A, Brill L, et al
Altered immune co-inhibitory receptor expression and correlation of LAG-3
expression to disease severity in NMOSD.
J Neuroimmunol. 2024;388:578289.
J Neurol
- KRIJNEN EA, Broeders TAA, Noteboom S, van Dam M, et al
The cognitive relevance of non-lesional damage to cortical networks in people
with multiple sclerosis.
J Neurol. 2024 Mar 5. doi: 10.1007/s00415-024-12240.
- HEGEN H, Berek K, Deisenhammer F, Berger T, et al
Sex impacts treatment decisions in multiple sclerosis.
J Neurol. 2024 Mar 5. doi: 10.1007/s00415-024-12270.
- HECHENBERGER S, Helmlinger B, Tinauer C, Jauk E, et al
Evaluation of a self-administered iPad((R))-based processing speed assessment for
people with multiple sclerosis in a clinical routine setting.
J Neurol. 2024 Mar 5. doi: 10.1007/s00415-024-12274.
- ZID Y, Robertson NP
Extended interval dosing strategies in multiple sclerosis: insights from
natalizumab and ocrelizumab trials.
J Neurol. 2024 Mar 4. doi: 10.1007/s00415-024-12273.
- GUGER M, Enzinger C, Leutmezer F, Di Pauli F, et al
Early intensive versus escalation treatment in patients with relapsing-remitting
multiple sclerosis in Austria.
J Neurol. 2024 Mar 2. doi: 10.1007/s00415-024-12256.
J Neurol Neurosurg Psychiatry
- FOONG YC, Merlo D, Gresle M, Buzzard K, et al
Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple
sclerosis over age 60.
J Neurol Neurosurg Psychiatry. 2024 Mar 7:jnnp-2023-332883.
- JING J, Zhang Z, Su L, Gao C, et al
Central vein sign and trigeminal lesions of multiple sclerosis visualised by 7T
MRI.
J Neurol Neurosurg Psychiatry. 2024 Mar 7:jnnp-2023-332566.
Mult Scler
- MONTALBAN X, Piasecka-Stryczynska K, Kuhle J, Benkert P, et al
Efficacy and safety results after >3.5 years of treatment with the Bruton's
tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term
follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid
sub-study.
Mult Scler. 2024 Mar 4:13524585241234783. doi: 10.1177/13524585241234783.
- APREA MG, Schiavetti I, Portaccio E, Ballerini C, et al
Impact of COVID-19 on pregnancy and fetal outcomes in women with multiple
sclerosis.
Mult Scler. 2024 Mar 8:13524585241232266. doi: 10.1177/13524585241232266.
- HILLERT J, Bove R, Haddad LB, Hellwig K, et al
Expert opinion on the use of contraception in people with multiple sclerosis.
Mult Scler. 2024 Mar 8:13524585241228103. doi: 10.1177/13524585241228103.
Nat Rev Neurol
- FYFE I
Mitochondrial DNA marks multiple sclerosis.
Nat Rev Neurol. 2024 Mar 5. doi: 10.1038/s41582-024-00948.
Neurology
- OLIVE-CIRERA G, Bruijstens AL, Fonseca EG, Chen LW, et al
MOG Antibodies Restricted to CSF in Children With Inflammatory CNS Disorders.
Neurology. 2024;102:e209199.
- SPELMAN T, Simoneau G, Hyde R, Kuhelj R, et al
Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in
Pediatric-Onset Multiple Sclerosis: A Registry-Based Study.
Neurology. 2024;102:e208114.
PLoS One
- JOZEF M, Locatelli I, Brecl Jakob G, Savsek L, et al
Psychometric evaluation of the 5-item Medication Adherence Report Scale
questionnaire in persons with multiple sclerosis.
PLoS One. 2024;19:e0294116.
Rev Neurol (Paris)
- HAY M, Leguy S, Cahagne V, Lassalle N, et al
Fatal natalizumab-associated progressive multifocal leukoencephalopathy with
initial low JCV antibody index in a multiple sclerosis patient.
Rev Neurol (Paris). 2024 Feb 29:S0035-3787(24)00371.
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016